Imatinib treatment and Aβ42 in humans
B Olsson, L Legros, F Guilhot, K Strömberg… - Alzheimer's & …, 2014 - Elsevier
Background The first-line treatment in chronic myeloid leukemia (CML), imatinib, has been
shown to decrease the production of amyloid-β (Aβ) in vitro and in animal studies. However,
whether imatinib has this effect in humans is not known. Methods Plasma levels of Aβ42
were analyzed in sequential samples from CML patients treated with imatinib (n= 51). The
effect of imatinib on Aβ production was also investigated in human embryonic kidney 293
(HEK293) cells overexpressing the amyloid precursor protein (APP) with the Swedish …
shown to decrease the production of amyloid-β (Aβ) in vitro and in animal studies. However,
whether imatinib has this effect in humans is not known. Methods Plasma levels of Aβ42
were analyzed in sequential samples from CML patients treated with imatinib (n= 51). The
effect of imatinib on Aβ production was also investigated in human embryonic kidney 293
(HEK293) cells overexpressing the amyloid precursor protein (APP) with the Swedish …